Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

1

Patients with Philadelphia-negative MPNs have a high Covid19 mortality rate, particularly in myelofibrosis, reaching 48%.
2

Ruxolitinib treatment is associated with altered immune responses, increasing the risk of SARS-CoV-2 infection and poor outcomes.
3

Vaccination significantly reduces the risk of Covid19 infection in ruxolitinib-treated patients, with 79.4% having received at least one vaccine dose.
4

Hospitalization rates for severe Covid19 infections were higher during the first two pandemic waves compared to the third wave.
5

Older age, lower platelet counts, and comorbidities are significant factors associated with hospitalization and mortality in Covid19 patients.

Blood Cancer Journal

by Francesca Palandri, Elena M. Elli, Giuseppe Auteri, Massimiliano Bonifacio, Giulia Benevolo, Florian H. Heidel, Simona Paglia, Malgorzata M. Trawinska, Costanza Bosi, Elena Rossi, Mario Tiribelli, Alessia Tieghi, Alessandra Iurlo, Nicola Polverelli, Giovanni Caocci, Gianni Binotto, Francesco Cavazzini, Eloise Beggiato, Daniela Cilloni, Caterina Tatarelli, Francesco Mendicino, Maurizio Miglino, Monica Bocchia, Monica Crugnola, Camilla Mazzoni, Andrea D. Romagnoli, Giovanni Rindone, Sara Ceglie, Alessandra D’Addio, Eleonora Santoni, Daniele Cattaneo, Daniela Bartoletti, Roberto M. Lemoli, Mauro Krampera, Antonio Cuneo, Gianpietro C. Semenzato, Roberto Latagliata, Elisabetta Abruzzese, Nicola Vianelli, Michele Cavo, Alessandro Andriani, Valerio De Stefano, Giuseppe A. Palumbo, Massimo Breccia
May 3, 2023

1